AbbVie Inc. ABBV, +1.94% on Friday reported fourth-quarter sales that topped analysts’ estimates, even as it faces low-cost competition for its top-selling drug, Humira. The drugmaker reported fourth-quarter net income of $822 million, or 46 cents per share, down sharply from $2.473 billion, or $1.38 per share, in the year-earlier period. Adjusted earnings per share of $2.79, which included an unfavorable impact of 15 cents a share related to acquired in-process research and development expenses, matched th ...

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results Include an Unfavorable Impact of $0.42 Per Share Related to 2023 Acquired IPR&D and Milestones Expense  Delivers Full-Year Net Revenues of $54.318 Billion, a Decrease of 6.4 Percent on a Reported Basis and 5.9 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $26.136 Billion, a Decrease of 9.6 Percent on ...

There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly. Analysts expect compound annual growth approaching 13% between the years 2023 and 2030.There’s a lot going on within the sector that will serve to prompt that growth. Artificial intelligence has important applications to the biotechnology sector. CRISPR gene editing technology continues to evolve  including new applications at the commercial level. ...

-- New report incorporates in-depth interviews, industry research and social listening to understand the role of individuality in the world of aesthetics ---- Report underpins ongoing commitment to aesthetics accessibility and inclusivity to achieve desired patient outcomes --IRVINE, Calif., Jan. 31, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie (NYSE: ABBV) company and a global leader in medical aesthetics treatments, released the "Decoding the Future of Aesthetic Individuality" report, which ...

In its upcoming report, AbbVie (ABBV) is predicted by Wall Street analysts to post quarterly earnings of $2.79 per share, reflecting a decline of 22.5% compared to the same period last year. Revenues are forecasted to be $14.06 billion, representing a year-over-year decrease of 7%.Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forec ...

We see daily analyst upgrades and downgrades, coming with price targets. They can be helpful tools for investors, providing a more structured plan and helping to inject positivity surrounding future performance.Of course, stocks don’t straightforwardly reach price targets, as unforeseen circumstances can always influence performance. Overall, the positive shift in sentiment can be seen as a primary takeaway from these upgrades.  Recently, three stocks – AbbVie (ABBV) , Hershey (HSY) , and Dollar Tree (DLTR) ...

The most recent trading session ended with AbbVie (ABBV) standing at $163.91, reflecting a -0.3% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.76%. On the other hand, the Dow registered a gain of 0.59%, and the technology-centric Nasdaq increased by 1.12%.Shares of the drugmaker witnessed a gain of 6.09% over the previous month, beating the performance of the Medical sector with its gain of 1.57% and the S&P 500's gain of 2.5%.Investors wil ...

There's one constant you can always rely on. Regardless of what's happening to the overall economy, people keep racking up higher healthcare bills as they get older. And nowadays there are more folks racking up those bills.From 1920 through 2020, America's over-65 population grew nearly five times faster than the total population.Aging baby boomers pushed older population growth into high gear during the decade between 2010 and 2020. In the latest U.S. Census, the number of over-65 adults rose 38% to 56 mil ...

Jun/iStock via Getty Images Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a clinical-stage biotechnology company focusing on developing treatments for immune-mediated inflammatory diseases. Its leading drug candidate is Reproxalap for dry eye and allergic conjunctivitis. It is a RASP modulator that reduces the generation of pro-inflammatory cytokines, a critical step for treating various ocular conditions. ALDX will resubmit in the first semester of 2024 the FDA approval request for this drug applied to d ...

Core Insights - The healthcare sector had a mediocre performance in 2023, finishing just over the positive mark, primarily due to its lack of participation in the tech sector's growth [1] - Despite the overall performance, healthcare remains a suitable option for diversified portfolios due to its defensive characteristics and steady demand [1] - AbbVie Inc. (ABBV) and Merck & Co., Inc. (MRK) are highlighted as attractive investment opportunities within the healthcare space, both providing steady and growing dividends [1][2] Healthcare Sector Performance - The healthcare sector's performance was in line with broader market trends, with the Health Care Select Sector SPDR® Fund ETF (XLV) showing ABBV and MRK as top holdings [2][3] - The sector's performance was overshadowed by the tech sector, particularly the "Magnificent 7" companies [1] AbbVie Inc. (ABBV) - ABBV faced challenges due to the Humira patent cliff, which negatively impacted earnings expectations for 2023 and 2024, but analysts anticipate a return to growth in 2025 [4][16] - The company has diversified its product offerings with new drugs like Skyrizi and Rinvoq, which have shown significant sales growth [5][6] - ABBV raised its adjusted EPS guidance for FY 2023 to a range of $11.19 to $11.23 and also increased the EPS guidance floor for FY 2024 to $10.70 to $11 [7] - The company has a history of consistent dividend increases, marking 10 consecutive years of growth, with expectations for an 11th year in 2024 [8][16] Merck & Co., Inc. (MRK) - MRK's primary revenue driver is Keytruda, which accounts for approximately 36.27% of total sales, with other drugs like Gardasil and Lagevrio also contributing to growth [9][12] - In Q3 2023, MRK reported total sales of $15.962 billion, a 7% increase from the previous year, with Keytruda sales growing by 17% [10] - The company is preparing for the patent expiration of Keytruda in 2028, similar to ABBV's situation with Humira, and is actively working on its drug pipeline [12][16] - MRK's dividend growth has been more modest compared to ABBV, but the company has maintained respectable earnings growth and free cash flow [13][14] Investment Considerations - Both ABBV and MRK offer attractive dividend yields of 3.8% and 2.6%, respectively, contributing to passive income for investors [16] - While ABBV's current earnings are under pressure, potential growth is expected post-Humira transition, while MRK is focused on sustaining growth until Keytruda's patent expiration [16]